| Literature DB >> 31035902 |
Shinichi Wada1, Masatoshi Koga1, Kazuo Minematsu1, Kazunori Toyoda1, Rieko Suzuki1, Tatsuo Kagimura2, Yoji Nagai3, Shiro Aoki4, Tomohisa Nezu4, Naohisa Hosomi4, Hideki Origasa5, Toshiho Ohtsuki4,6, Hirofumi Maruyama4, Masahiro Yasaka4,7, Kazuo Kitagawa8, Shinichiro Uchiyama9, Masayasu Matsumoto10.
Abstract
Background and Purpose- As a prespecified post hoc analysis of the J-STARS (Japan Statin Treatment Against Recurrent Stroke) Echo Study, the 5-year stroke recurrence rate according to the baseline mean carotid intima-media thickness (IMT) with and without pravastatin treatment was investigated. Methods- Patients were randomly assigned to receive pravastatin 10 mg/day (pravastatin group) or control group (nonstatin treatment; 1:1) for 5 years. Baseline mean IMT of the common carotid artery was measured by ultrasonography. Cox proportional hazards models were used to investigate whether the stroke (any ischemic stroke, atherothrombotic brain infarction, or lacunar infarction) recurrence rate was different according to tertiles of baseline mean IMT. Results- A total of 793 patients, including 388 in the pravastatin group and 405 in the control group, were investigated. In the control group, Cox proportional hazards models showed that participants in the highest tertile IMT group (≥0.931 mm) had a higher rate of atherothrombotic brain infarction than those in the lowest tertile IMT group (<0.812 mm; [hazard ratio, 9.08; 95% CI, 1.15-71.43]). Patients in the pravastatin group had a lower risk of atherothrombotic brain infarction than those in the control group only in the highest tertile IMT group by the log-rank test ( P value=0.045). Conclusions- Long-term pravastatin administration may prevent the occurrence of atherothrombotic brain infarction in noncardioembolic infarction patients with the highest tertile IMT. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT00361530.Entities:
Keywords: brain infarction; carotid intima-media thickness; hypercholesterolemia; pravastatin; secondary prevention
Year: 2019 PMID: 31035902 DOI: 10.1161/STROKEAHA.119.024968
Source DB: PubMed Journal: Stroke ISSN: 0039-2499 Impact factor: 7.914